Elgia Therapeutics is developing small molecule drugs targeting caspase and kinase pathways to address metabolic inflammation and fibrosis in chronic diseases. The company's research focuses on untapped protein targets, enabling the rapid advancement of first-in-class therapies through a robust drug discovery platform.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic stress drives inflammation and fibrosis, contributing to the pathology of many chronic diseases. Current treatments often lack specificity and efficacy, leaving a significant unmet need for targeted therapies.
Solution
Elgia Therapeutics is developing first-in-class small molecule drugs that target previously untapped protein targets within caspase and kinase pathways to address metabolic inflammation and fibrosis. By focusing on these novel targets, Elgia aims to create innovative medicines for debilitating chronic diseases. The company's drug discovery platform combines pioneering biological insights with expertise in research and development to rapidly advance promising therapeutic candidates. This approach allows for the development of therapies with unique mechanisms of action, improved efficacy, and enhanced safety profiles.
Target Audience
Elgia's primary target audience includes patients suffering from chronic diseases characterized by metabolic inflammation and fibrosis, as well as pharmaceutical companies seeking innovative therapeutic candidates for licensing or co-development.
Features
- Focus on small molecule drugs targeting caspase and kinase pathways.
- Identification of novel, previously untapped protein targets.
- Drug discovery platform integrating biological insights and R&D expertise.
- Advanced chemical matter and structure-based drug design (SBDD).
- Emphasis on efficacy and safety in drug development.
- Potential for multiple clinical applications in metabolic, inflammatory, and fibrotic diseases.